An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia

Background The artemisinin-based combination treatment (ACT) of dihydroartemisinin (DHA) and piperaquine (PQP) is a promising novel anti-malarial drug effective against multi-drug resistant falciparum malaria. The aim of this study was to show non-inferiority of DHA/PQP vs. artesunate-mefloquine (AS+MQ) in Asia. Methods and Findings This was an open-label, randomised, non-inferiority, 63-day follow-up study conducted in Thailand, Laos and India. Patients aged 3 months to 65 years with Plasmodium falciparum mono-infection or mixed infection were randomised with an allocation ratio of 2∶1 to a fixed-dose DHA/PQP combination tablet (adults: 40 mg/160 mg; children: 20 mg/320 mg; n = 769) or loose combination of AS+MQ (AS: 50 mg, MQ: 250 mg; n = 381). The cumulative doses of study treatment over the 3 days were of about 6.75 mg/kg of DHA and 54 mg/kg of PQP and about 12 mg/kg of AS and 25 mg/kg of MQ. Doses were rounded up to the nearest half tablet. The primary endpoint was day-63 polymerase chain reaction (PCR) genotype-corrected cure rate. Results were 87.9% for DHA/PQP and 86.6% for AS+MQ in the intention-to-treat (ITT; 97.5% one-sided confidence interval, CI: >−2.87%), and 98.7% and 97.0%, respectively, in the per protocol population (97.5% CI: >−0.39%). No country effect was observed. Kaplan-Meier estimates of proportions of patients with new infections on day 63 (secondary endpoint) were significantly lower for DHA/PQP than AS+MQ: 22.7% versus 30.3% (p = 0.0042; ITT). Overall gametocyte prevalence (days 7 to 63; secondary endpoint), measured as person-gametocyte-weeks, was significantly higher for DHA/PQP than AS+MQ (10.15% versus 4.88%; p = 0.003; ITT). Fifteen serious adverse events were reported, 12 (1.6%) in DHA/PQP and three (0.8%) in AS+MQ, among which six (0.8%) were considered related to DHA/PQP and three (0.8%) to AS+MQ. Conclusions DHA/PQP was a highly efficacious drug for P. falciparum malaria in areas where multidrug parasites are prevalent. The DHA/PQP combination can play an important role in the first-line treatment of uncomplicated falciparum malaria. Trial Registration Controlled-Trials.com ISRCTN81306618

[1]  Renuka Kunte,et al.  WHO Guidelines for the treatment of malaria , 2011 .

[2]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[3]  P. Newton,et al.  Safety and Efficacy of Dihydroartemisinin-Piperaquine in Falciparum Malaria: A Prospective Multi-Centre Individual Patient Data Analysis , 2009, PloS one.

[4]  Stephane Proux,et al.  Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment , 2009, PloS one.

[5]  M. Fukuda,et al.  Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.

[6]  P. Siba,et al.  A trial of combination antimalarial therapies in children from Papua New Guinea. , 2008, The New England journal of medicine.

[7]  S. Meshnick,et al.  Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia–Thailand Border , 2008, Emerging infectious diseases.

[8]  N. White,et al.  Qinghaosu (Artemisinin): The Price of Success , 2008, Science.

[9]  H. Myint,et al.  Efficacy and safety of dihydroartemisinin-piperaquine. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[10]  N. White.  Cardiotoxicity of antimalarial drugs. , 2007, The Lancet. Infectious diseases.

[11]  P. Newton,et al.  Combined molecular and clinical assessment of Plasmodium falciparum antimalarial drug resistance in the Lao People's Democratic Republic (Laos). , 2007, The American journal of tropical medicine and hygiene.

[12]  R. Price,et al.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison , 2007, The Lancet.

[13]  P. Newton,et al.  In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos). , 2007, The American journal of tropical medicine and hygiene.

[14]  F. Nosten,et al.  An open label randomized comparison of mefloquine–artesunate as separate tablets vs. a new co‐formulated combination for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand , 2006, Tropical medicine & international health : TM & IH.

[15]  P. Newton,et al.  An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos) , 2006, Tropical medicine & international health : TM & IH.

[16]  K. Stepniewska,et al.  Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison , 2006, The Lancet.

[17]  C. Rogers,et al.  A randomized trial comparing the efficacy of four treatment regimens for uncomplicated falciparum malaria in Assam state, India. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[18]  N. Day,et al.  Pitfalls in Estimating Piperaquine Elimination , 2005, Antimicrobial Agents and Chemotherapy.

[19]  F. Nosten,et al.  A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand , 2005, Malaria Journal.

[20]  F. Nosten,et al.  A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Ward,et al.  In vitro antimalarial drug susceptibility in Thai border areas from 1998–2003 , 2005, Malaria Journal.

[22]  F. Nosten,et al.  Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. , 2004, The Journal of infectious diseases.

[23]  T. Jelínek,et al.  Therapeutic efficacy of artemether‐lumefantrine and artesunate‐mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic , 2004, Tropical medicine & international health : TM & IH.

[24]  P. Newton,et al.  Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  C. Dolecek,et al.  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial , 2004, The Lancet.

[26]  S. Hewitt,et al.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. , 2003, British journal of clinical pharmacology.

[27]  P. Newton,et al.  A randomized comparison of oral chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in Laos. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  S. Hewitt,et al.  Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. , 2002, Clinical Infectious Diseases.

[29]  S. Krudsood,et al.  Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand. , 2002, The American journal of tropical medicine and hygiene.

[30]  S. Krudsood,et al.  A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. , 2001, The American journal of tropical medicine and hygiene.

[31]  Leon Aarons,et al.  Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance , 2000, Antimicrobial Agents and Chemotherapy.

[32]  N. White,et al.  Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[33]  Richard N. Price,et al.  Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.

[34]  M. Coosemans,et al.  Glucose‐6‐phosphate dehydrogenase deficiency in northern Vietnam , 2000, Tropical medicine & international health : TM & IH.

[35]  N. White,et al.  Randomized Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in Treatment of MultidrugResistant Falciparum Malaria , 1998, Antimicrobial Agents and Chemotherapy.

[36]  R. Paru,et al.  Mating patterns in malaria parasite populations of Papua New Guinea. , 1995, Science.

[37]  O. Doumbo,et al.  Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. , 1995, The American journal of tropical medicine and hygiene.

[38]  R. Carter,et al.  Frequency of cross-fertilization in the human malaria parasite Plasmodium falciparum , 1993, Parasitology.

[39]  L Chen,et al.  Field observations on the antimalarial piperaquine. , 1982, Chinese medical journal.

[40]  P. Singhasivanon,et al.  In vitro susceptibility and genetic variations for chloroquine and mefloquine in Plasmodium falciparum isolates from Thai-Myanmar border. , 2005, The Southeast Asian journal of tropical medicine and public health.

[41]  Geneva,et al.  ANTIMALARIAL DRUG COMBINATION THERAPY Report of a WHO Technical Consultation , 2022 .